東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Direct-to-consumer promotion of pres...

Teleki, Stephanie Ilona Shipley.

Linked to FindBook

Google Book

Amazon

博客來

Direct-to-consumer promotion of prescription drugs: The case of COX-2 inhibitors.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Direct-to-consumer promotion of prescription drugs: The case of COX-2 inhibitors./
Author:	Teleki, Stephanie Ilona Shipley.
Description:	320 p.
Notes:	Chair: Stuart O. Schweitzer.
Contained By:	Dissertation Abstracts International63-03B.
Subject:	Business Administration, Marketing. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3045607
ISBN:	0493595481

Direct-to-consumer promotion of prescription drugs: The case of COX-2 inhibitors.
Teleki, Stephanie Ilona Shipley.

Direct-to-consumer promotion of prescription drugs: The case of COX-2 inhibitors. - 320 p.

Chair: Stuart O. Schweitzer.

Thesis (Ph.D.)--University of California, Los Angeles, 2002.

This research examined the impact of direct-to-consumer (DTC) promotion of COX-2 inhibitors on the likelihood of receiving a medically inappropriate prescription for a COX-2 inhibitor. Surveys were mailed to a stratified, random sample of nearly 3,000 Kaiser Permanente members who: (1) filled a new prescription for either a COX-2 inhibitor (i.e., Celebrex™ and Vioxx<super> ®</super>) or a traditional, non-steroidal anti-inflammatory drug (“NSAID”) during a three-month window, and (2) met additional study criteria. Medical appropriateness was measured using the Standardized Calculator of Risk for Events (SCORE<super>©</super>) tool. Additional information was obtained from administrative databases. A statistically significant and strong association between medically inappropriate COX-2 inhibitor utilization and awareness of DTC promotion of these drugs was found. Respondents who reported having seen or heard an advertisement for a COX-2 inhibitor were almost 5 times as likely to have been inappropriately treated with a COX-2 inhibitor compared to similar respondents who did not see or hear an advertisement, net all other factors in the model. Even more striking, respondents who reported having seen or heard an advertisement for a COX-2 inhibitor <italic>and</italic> having asked their physician about these drugs were found to be 11 times as likely to have been inappropriately treated with a COX-2 inhibitor. Patient age and physician medical specialty were also found to be significantly associated with inappropriate treatment. In this study, cost implications to the health plan relating to inappropriate prescriptions were also examined. The results of this research suggest that DTC advertising leads to the treatment of patients with drugs that may not be medically necessary and that are substantially more expensive than alternative drug therapies.

ISBN: 0493595481Subjects--Topical Terms:

1017573
Business Administration, Marketing.

Direct-to-consumer promotion of prescription drugs: The case of COX-2 inhibitors.
LDR:02884nam 2200313 a 45 001 937929
005 20110511
008 110511s2002 eng d
020 $a 0493595481
035 $a (UnM)AAI3045607
035 $a AAI3045607
040 $a UnM $c UnM
100 1 $a Teleki, Stephanie Ilona Shipley. $3 1261785
245 1 0 $a Direct-to-consumer promotion of prescription drugs: The case of COX-2 inhibitors.
300 $a 320 p.
500 $a Chair: Stuart O. Schweitzer.
500 $a Source: Dissertation Abstracts International, Volume: 63-03, Section: B, page: 1321.
502 $a Thesis (Ph.D.)--University of California, Los Angeles, 2002.
520 $a This research examined the impact of direct-to-consumer (DTC) promotion of COX-2 inhibitors on the likelihood of receiving a medically inappropriate prescription for a COX-2 inhibitor. Surveys were mailed to a stratified, random sample of nearly 3,000 Kaiser Permanente members who: (1) filled a new prescription for either a COX-2 inhibitor (i.e., Celebrex™ and Vioxx<super> ®</super>) or a traditional, non-steroidal anti-inflammatory drug (“NSAID”) during a three-month window, and (2) met additional study criteria. Medical appropriateness was measured using the Standardized Calculator of Risk for Events (SCORE<super>©</super>) tool. Additional information was obtained from administrative databases. A statistically significant and strong association between medically inappropriate COX-2 inhibitor utilization and awareness of DTC promotion of these drugs was found. Respondents who reported having seen or heard an advertisement for a COX-2 inhibitor were almost 5 times as likely to have been inappropriately treated with a COX-2 inhibitor compared to similar respondents who did not see or hear an advertisement, net all other factors in the model. Even more striking, respondents who reported having seen or heard an advertisement for a COX-2 inhibitor <italic>and</italic> having asked their physician about these drugs were found to be 11 times as likely to have been inappropriately treated with a COX-2 inhibitor. Patient age and physician medical specialty were also found to be significantly associated with inappropriate treatment. In this study, cost implications to the health plan relating to inappropriate prescriptions were also examined. The results of this research suggest that DTC advertising leads to the treatment of patients with drugs that may not be medically necessary and that are substantially more expensive than alternative drug therapies.
590 $a School code: 0031.
650 4 $a Business Administration, Marketing. $3 1017573
650 4 $a Health Sciences, Health Care Management. $3 1017922
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Health Sciences, Public Health. $3 1017659
650 4 $a Political Science, Public Administration. $3 1017438
690 $a 0338
690 $a 0572
690 $a 0573
690 $a 0617
690 $a 0769
710 2 0 $a University of California, Los Angeles. $3 626622
773 0 $t Dissertation Abstracts International $g 63-03B.
790 $a 0031
790 1 0 $a Schweitzer, Stuart O., $e advisor
791 $a Ph.D.
792 $a 2002
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3045607